PMID- 23554297
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20220408
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Linking)
VI  - 65
IP  - 9
DP  - 2013 Sep
TI  - Safety and immunogenicity of yellow fever 17D vaccine in adults receiving 
      systemic corticosteroid therapy: an observational cohort study.
PG  - 1522-8
LID - 10.1002/acr.22021 [doi]
AB  - OBJECTIVE: To assess the safety and immunogenicity of live attenuated yellow 
      fever (YF) 17D vaccine in adults receiving systemic corticosteroid therapy. 
      METHODS: All adult travelers on systemic corticosteroid therapy who had received 
      the YF17D vaccine in 24 French vaccination centers were prospectively enrolled 
      and matched with healthy controls (1:2) on age and history of YF17D immunization. 
      Safety was assessed in a self-administered standardized questionnaire within 10 
      days after immunization. YF-specific neutralizing antibody titers were measured 6 
      months after vaccination in patients receiving corticosteroids. RESULTS: Between 
      July 2008 and February 2011, 102 vaccine recipients completed the safety study 
      (34 receiving corticosteroids and 68 controls). The median age was 54.9 years 
      (interquartile range [IQR] 45.1-60.3 years) and 45 participants had a history of 
      previous YF17D immunization. The median time receiving corticosteroid therapy was 
      10 months (IQR 1-67 months) and the prednisone or equivalent dosage was 7 mg/day 
      (IQR 5-20). Main indications were autoimmune diseases (n = 14), rheumatoid 
      arthritis (n = 9), and upper respiratory tract infections (n = 8). No serious 
      adverse event was reported; however, patients receiving corticosteroids reported 
      more frequent moderate/severe local reactions than controls (12% and 2%, 
      respectively; relative risk 8.0, 95% confidence interval 1.4-45.9). All subjects 
      receiving corticosteroids who were tested (n = 20) had neutralizing antibody 
      titers >10 after vaccination. CONCLUSION: After YF17D immunization, 
      moderate/severe local reactions may be more frequent in patients receiving 
      systemic corticosteroid therapy. Immunogenicity seems satisfactory. Large-scale 
      studies are needed to confirm these results.
CI  - Copyright (c) 2013 by the American College of Rheumatology.
FAU - Kerneis, Solen
AU  - Kerneis S
AD  - Paris Descartes University, INSERM, CIC BT505, and AP-HP, Cochin Hospital, 
      CICBT505, Paris, France.
FAU - Launay, Odile
AU  - Launay O
FAU - Ancelle, Thierry
AU  - Ancelle T
FAU - Iordache, Laura
AU  - Iordache L
FAU - Naneix-Laroche, Veronique
AU  - Naneix-Laroche V
FAU - Mechai, Frederic
AU  - Mechai F
FAU - Fehr, Thierry
AU  - Fehr T
FAU - Leroy, Jean-Philippe
AU  - Leroy JP
FAU - Issartel, Bertrand
AU  - Issartel B
FAU - Dunand, Jean
AU  - Dunand J
FAU - van der Vliet, Diane
AU  - van der Vliet D
FAU - Wyplosz, Benjamin
AU  - Wyplosz B
FAU - Consigny, Paul-Henri
AU  - Consigny PH
FAU - Hanslik, Thomas
AU  - Hanslik T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Yellow Fever Vaccine)
SB  - IM
MH  - Adrenal Cortex Hormones/*administration & dosage/adverse effects
MH  - Adult
MH  - Arthralgia/chemically induced/immunology
MH  - Cohort Studies
MH  - Fatigue/chemically induced/immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - Yellow Fever/epidemiology/*immunology/*prevention & control
MH  - Yellow Fever Vaccine/adverse effects/*immunology/*therapeutic use
MH  - Yellow fever virus/immunology
EDAT- 2013/04/05 06:00
MHDA- 2013/11/20 06:00
CRDT- 2013/04/05 06:00
PHST- 2012/08/16 00:00 [received]
PHST- 2013/03/20 00:00 [accepted]
PHST- 2013/04/05 06:00 [entrez]
PHST- 2013/04/05 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
AID - 10.1002/acr.22021 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2013 Sep;65(9):1522-8. doi: 10.1002/acr.22021.